SHANGHAI, CHINA – 2025/11/08: The logo of Boston Scientific with the slogan “Innovate for Life” is shown at the 8th China International Import Expo. (Photo by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)
SOPA Images/LightRocket via Getty Images
Boston Scientific (BSX) shares have decreased by 8.5% over the past 5 trading days. This recent drop highlights revived worries regarding the initial earnings dilution stemming from its Penumbra acquisition, yet such significant declines often raise a challenging question: is this weakness transitory, or does it indicate more profound issues within the company? As an aside, see 3 Catalysts To Watch Out For Google Stock.
Before assessing its downturn resilience, let’s examine Boston Scientific’s current position.
Size: Boston Scientific is a $133 billion company with $19 billion in revenue, currently trading at $90.03.Fundamentals: It has achieved a revenue growth of 21.6% over the last 12 months, along with an operating margin of 19.2%.Liquidity: The company maintains a Debt to Equity ratio of 0.09 and a Cash to Assets ratio of 0.03.Valuation: Boston Scientific’s stock is presently trading at a P/E multiple of 47.8 and a P/EBIT multiple of 37.0.Since 2010, there has been one instance where the stock dipped >30% in <30 days and later recovered by 41.1% within a year. Refer to BSX Dip Buy Analysis.
These indicators suggest Strong operational performance, coupled with a Very High valuation, rendering the stock Relatively Expensive. For further information, see Buy or Sell BSX Stock.
This leads us to a crucial consideration for investors concerned about this decline: how resilient is BSX stock if the market declines? This is where our downturn resilience framework becomes relevant. If BSX stock drops another 20-30% to $63, will investors be able to hold on comfortably? It turns out that the stock experienced a response slightly worse than the S&P 500 index during various economic downturns, based on (a) how much the stock decreased and (b) how quickly it bounced back. Below, we delve deeper into each downturn.
2022 Inflation ShockBSX stock fell 25.2% from a peak of $47.10 on 20 April 2022 to $35.24 on 14 June 2022, compared to a peak-to-trough decline of 25.4% in the S&P 500.Nonetheless, the stock completely regained its pre-crisis peak by 12 December 2022.Since then, the stock has risen to a high of $108.14 on 8 September 2025 and is currently trading at $90.03.
BSX Stock Performance During The 2022 Inflation Shock
Trefis2020 Covid PandemicBSX stock declined 43.5% from a high of $45.71 on 9 January 2020 to $25.83 on 23 March 2020, compared to a peak-to-trough decline of 33.9% in the S&P 500.Nevertheless, the stock completely recovered to its pre-crisis peak by 2 August 2021.
BSX Stock Performance During The 2020 COVID Pandemic
Trefis2018 CorrectionBSX stock fell 18.7% from a peak of $39.04 on 2 October 2018 to $31.73 on 24 December 2018, compared to a peak-to-trough decline of 19.8% in the S&P 500.Nevertheless, the stock fully recovered to its pre-crisis peak by 8 February 2019.
BSX Stock Performance During The 2018 Correction
Trefis2008 Global Financial CrisisBSX stock decreased by 70.5% from a peak of $18.59 on 30 January 2007 to $5.48 on 20 November 2008, compared to a peak-to-trough decline of 56.8% for the S&P 500.However, the stock completely regained its pre-crisis peak by 2 November 2015.
BSX Stock Performance During The 2008 Financial Crisis
Trefis
Feeling anxious about BSX stock? Consider a portfolio strategy.
Portfolios Succeed When Individual Stocks Underperform
Stock prices can fluctuate drastically – the essential aspect is remaining invested. A well-rounded portfolio keeps you in the market, enhances gains, and mitigates the risks associated with individual stocks.
The Trefis High Quality (HQ) Portfolio, featuring a selection of 30 stocks, has a consistent record of significantly outperforming its benchmark, which includes all three – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is this the case? As a collective, HQ Portfolio stocks have yielded superior returns with lower risk compared to the benchmark; providing a more stable investment experience, as evidenced by HQ Portfolio performance metrics.